Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BHAKTASHARAN C PATEL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1053415463
CMS profile
183770
Location
COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$9,453.38

62 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,125.00 1
Food and Beverage $1,770.69 56
Travel and Lodging $1,549.24 4
Education $8.45 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BHAKTASHARAN C PATEL

NPI 1053415463 · CMS profile ID 183770

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053415463?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BHAKTASHARAN C PATEL, NPI 1053415463, CMS profile ID 183770. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053415463?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BHAKTASHARAN C PATEL, NPI 1053415463, CMS profile ID 183770. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053415463?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BHAKTASHARAN C PATEL, NPI 1053415463, CMS profile ID 183770, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1053415463?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

62 matching records · $9,453.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 62 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–62 of 62.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $96.1503/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022549637 CMS
GENZYME CORPORATION $15.1203/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050103995 CMS
Boston Scientific Corporation $56.4503/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022549633 CMS
QOL Medical, LLC $21.0102/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059262359 CMS
Novo Nordisk Inc $52.8302/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002890673 CMS
Ferring Pharmaceuticals Inc. $16.8402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044220633 CMS
Janssen Biotech, Inc. $16.8202/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988056015 CMS
Janssen Scientific Affairs, LLC $32.5101/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988456993 CMS
ABBVIE INC. $9.0501/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998084007 CMS
ABBVIE INC. $14.7501/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998084005 CMS
PFIZER INC. $20.6301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050625881 CMS
Ferring Pharmaceuticals Inc. $16.6401/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044220623 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,522.62 26
PY2020 $3,077.96 20
PY2021 $474.57 22
PY2022 $3,059.55 35
PY2023 $9,453.38 62
PY2024 $9,682.45 129
PY2025 $2,371.87 69

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $64.26 1
PY2025 Principal investigator $1,147,400.95 447
PY2024 Recipient $988.18 7
PY2024 Principal investigator $1,506,607.67 224
PY2023 Recipient $1,732.50 1
PY2023 Principal investigator $1,888,822.04 111
PY2022 Principal investigator $3,650,287.52 212
PY2021 Recipient $289,855.91 4
PY2021 Principal investigator $10,765,392.47 321
PY2020 Principal investigator $2,106,543.20 148
PY2019 Recipient $1,923.61 12
PY2019 Principal investigator $883,667.25 120

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

448 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 12/29/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183321
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 12/29/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183365
Principal investigator 1 Janssen Research & Development, LLC $1,407.00 12/29/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? No dispute reported 06/30/2026 1175417664
Principal investigator 1 Genentech, Inc. $2,372.00 12/23/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC No dispute reported 06/30/2026 1211637263
Principal investigator 1 Boehringer Ingelheim International GmbH $3,491.10 12/19/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746976
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,073.54 12/19/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223289962
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,315.80 12/19/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050736
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,539.80 12/15/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Springs
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801108
Principal investigator 1 Ipsen Bioscience Inc. $96.90 12/11/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547013
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,124.10 12/11/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050738
Principal investigator 1 ABBVIE INC. $3,498.70 12/04/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202528794
Principal investigator 1 ABBVIE INC. $2,025.00 12/04/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202529000
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,441.40 12/04/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050740
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659074
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659076
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659078
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659080
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659082
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659084
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747056
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747058
Principal investigator 1 Ipsen Bioscience Inc. $90.00 12/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547015
Principal investigator 1 Boehringer Ingelheim International GmbH $3,659.85 11/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746972
Principal investigator 1 Boehringer Ingelheim International GmbH $3,491.10 11/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746974
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,579.00 11/26/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235994754
Principal investigator 1 Genentech, Inc. $6,728.00 11/25/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211637251
Principal investigator 1 Genentech, Inc. $2,342.00 11/25/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211637258
Principal investigator 1 Ipsen Bioscience Inc. $1,154.25 11/25/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547009
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,217.50 11/25/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050742
Recipient Eli Lilly and Company $64.26 11/20/2025 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187870947
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,036.10 11/20/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050744
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,720.70 11/20/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050746
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 11/19/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746846
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 11/19/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746848
Principal investigator 1 Genentech, Inc. $4,951.00 11/14/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211637256
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,354.10 11/14/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050748
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,427.98 11/07/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIAT
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223288149
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,229.50 11/07/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050750
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,036.10 11/07/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050752
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/06/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795263
Principal investigator 1 ABBVIE INC. $2,565.00 11/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202523007
Principal investigator 1 GlaxoSmithKline, LLC. $5,834.43 11/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192164079
Principal investigator 1 GlaxoSmithKline, LLC. $2,471.31 11/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192164086
Principal investigator 1 GlaxoSmithKline, LLC. $3,363.12 11/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192164095
Principal investigator 1 GlaxoSmithKline, LLC. $13,192.46 11/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192164661
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,901.37 11/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIAT
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223288017
Principal investigator 1 ABBVIE INC. $10,898.20 11/04/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202520229
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659062
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659064
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659066
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659068
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659070
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659072
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747052
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747054
Principal investigator 1 Ipsen Bioscience Inc. $90.00 11/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547011
Principal investigator 1 Janssen Research & Development, LLC $9,223.00 10/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? No dispute reported 06/30/2026 1175417720
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,713.90 10/29/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050754
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659086
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659088
Principal investigator 1 Boehringer Ingelheim International GmbH $766.50 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659090
Principal investigator 1 Boehringer Ingelheim International GmbH $24.36 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659092
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659094
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 10/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746970
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183139
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183155
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183203
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183248
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183256
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183288
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183330
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183349
Principal investigator 1 Janssen Research & Development, LLC $3,625.00 10/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183380
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,751.90 10/23/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050756
Principal investigator 1 Ipsen Bioscience Inc. $2,163.15 10/16/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547005
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,073.54 10/16/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223287019
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,205.10 10/16/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050758
Principal investigator 1 ABBVIE INC. $6,885.00 10/09/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202516315
Principal investigator 1 Genentech, Inc. $4,585.00 10/09/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211637249
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,422.60 10/09/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050760
Principal investigator 1 GlaxoSmithKline, LLC. $1,136.03 10/08/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192169216
Principal investigator 1 Ipsen Bioscience Inc. $6,463.80 10/03/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547003
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659050
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659052
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659054
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659056
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659058
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659060
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747048
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747050
Principal investigator 1 Ipsen Bioscience Inc. $90.00 10/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547007
Principal investigator 1 Janssen Research & Development, LLC $8,024.00 09/29/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175417725
Principal investigator 1 Boehringer Ingelheim International GmbH $4,392.90 09/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746962
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 09/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746964
Principal investigator 1 Boehringer Ingelheim International GmbH $1,883.25 09/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746966
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 09/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746968
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 09/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747008
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747010
Principal investigator 1 F. Hoffmann-La Roche AG $21,525.00 09/23/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211637246
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,451.90 09/23/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050762
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,236.30 09/18/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050764
Principal investigator 1 GlaxoSmithKline, LLC. $1,136.03 09/15/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192164639
Principal investigator 1 Ipsen Bioscience Inc. $1,121.95 09/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546999
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,998.50 09/12/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050734
Principal investigator 1 Janssen Research & Development, LLC $1,692.00 09/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175417654
Principal investigator 1 PFIZER INC. $920.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228742608
Principal investigator 1 PFIZER INC. $660.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228742944
Principal investigator 1 PFIZER INC. $3,120.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228743055
Principal investigator 1 PFIZER INC. $13,887.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228743251
Principal investigator 1 PFIZER INC. $3,000.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228743312
Principal investigator 1 PFIZER INC. $900.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228743572
Principal investigator 1 PFIZER INC. $20,259.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228754833
Principal investigator 1 PFIZER INC. $4,500.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228755090
Principal investigator 1 PFIZER INC. $2,360.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228755438
Principal investigator 1 PFIZER INC. $8,007.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228755567
Principal investigator 1 PFIZER INC. $3,000.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228755837
Principal investigator 1 PFIZER INC. $2,350.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228755968
Principal investigator 1 PFIZER INC. $1,890.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228756560
Principal investigator 1 PFIZER INC. $405.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228756724
Principal investigator 1 PFIZER INC. $4,000.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228757249
Principal investigator 1 PFIZER INC. $11,375.00 09/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228757263
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,913.88 09/05/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223285163
Principal investigator 1 Ipsen Bioscience Inc. $2,163.15 09/04/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546997
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,036.10 09/04/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050768
Principal investigator 1 ABBVIE INC. $1,163.10 09/03/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202507587
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659012
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659024
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659026
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659028
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659030
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659032
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659048
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747040
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747042
Principal investigator 1 Ipsen Bioscience Inc. $90.00 09/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547001
Principal investigator 1 Boehringer Ingelheim International GmbH $4,710.15 08/28/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746932
Principal investigator 1 Boehringer Ingelheim International GmbH $5,007.15 08/28/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746934
Principal investigator 1 Boehringer Ingelheim International GmbH $3,491.10 08/28/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746936
Principal investigator 1 Boehringer Ingelheim International GmbH $1,883.25 08/28/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746938
Principal investigator 1 Boehringer Ingelheim International GmbH $1,161.50 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746940
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746942
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746944
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746946
Principal investigator 1 Boehringer Ingelheim International GmbH $183.21 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746948
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746950
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746952
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746954
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746956
Principal investigator 1 Boehringer Ingelheim International GmbH $5.07 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746958
Principal investigator 1 Boehringer Ingelheim International GmbH $23.50 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746960
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747006
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747090
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,515.60 08/26/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050770
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,073.54 08/21/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223284467
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,769.00 08/21/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050772
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,112.10 08/14/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050774
Principal investigator 1 GlaxoSmithKline, LLC. $1,136.03 08/12/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167806
Principal investigator 1 Ipsen Bioscience Inc. $430.93 08/11/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546993
Principal investigator 1 Janssen Research & Development, LLC $55,496.00 08/11/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175417694
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,515.60 08/07/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050776
Principal investigator 1 ABBVIE INC. $7,190.00 08/06/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202503439
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659014
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659016
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659018
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659020
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659022
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659046
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747036
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747038
Principal investigator 1 Ipsen Bioscience Inc. $90.00 08/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546995
Principal investigator 1 Janssen Research & Development, LLC $1,692.00 07/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175417700
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,713.90 07/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050778
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 07/30/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746920
Principal investigator 1 Boehringer Ingelheim International GmbH $3,886.65 07/30/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746922
Principal investigator 1 Boehringer Ingelheim International GmbH $3,491.10 07/30/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746924
Principal investigator 1 Boehringer Ingelheim International GmbH $7,936.65 07/30/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746926
Principal investigator 1 Boehringer Ingelheim International GmbH $2,785.05 07/30/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746928
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 07/30/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746930
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 07/28/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183108
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 07/28/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183115
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 07/28/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183193
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183314
Principal investigator 1 Ipsen Bioscience Inc. $1,551.60 07/22/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546987
Principal investigator 1 Ipsen Bioscience Inc. $1,121.95 07/22/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546991
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,356.80 07/22/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050780
Principal investigator 1 GlaxoSmithKline, LLC. $1,136.03 07/17/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192169224
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,551.70 07/17/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050782
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,701.90 07/10/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050784
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,870.25 07/04/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223282242
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,031.20 07/04/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050786
Principal investigator 1 ABBVIE INC. $9,061.10 07/02/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202494627
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659034
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659036
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659038
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659040
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659042
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659044
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746840
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747002
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747044
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747046
Principal investigator 1 Ipsen Bioscience Inc. $90.00 07/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546989
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 06/30/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183132
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 06/30/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183178
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 06/30/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183374
Principal investigator 1 Janssen Research & Development, LLC $4,244.00 06/30/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Pa No dispute reported 06/30/2026 1175417649
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746836
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746838
Principal investigator 1 Boehringer Ingelheim International GmbH $1,883.25 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746882
Principal investigator 1 Boehringer Ingelheim International GmbH $3,886.65 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746884
Principal investigator 1 Boehringer Ingelheim International GmbH $5,007.15 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746886
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746888
Principal investigator 1 Boehringer Ingelheim International GmbH $2,785.05 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746890
Principal investigator 1 Boehringer Ingelheim International GmbH $4,710.15 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746892
Principal investigator 1 Boehringer Ingelheim International GmbH $7,936.65 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746894
Principal investigator 1 Boehringer Ingelheim International GmbH $3,659.85 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746896
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746898
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746900
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746902
Principal investigator 1 Boehringer Ingelheim International GmbH $2,052.00 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746904
Principal investigator 1 Boehringer Ingelheim International GmbH $1,883.25 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746906
Principal investigator 1 Boehringer Ingelheim International GmbH $4,392.90 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746908
Principal investigator 1 Boehringer Ingelheim International GmbH $12.60 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746998
Principal investigator 1 Boehringer Ingelheim International GmbH $85.60 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747000
Principal investigator 1 Boehringer Ingelheim International GmbH $12.60 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747086
Principal investigator 1 Boehringer Ingelheim International GmbH $85.60 06/24/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747088
Principal investigator 1 Ipsen Bioscience Inc. $1,242.74 06/24/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546983
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,229.50 06/24/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050788
Principal investigator 1 Ipsen Bioscience Inc. $2,163.15 06/19/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546979
Principal investigator 1 Ipsen Bioscience Inc. $2,312.10 06/19/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546981
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,733.10 06/19/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050790
Principal investigator 1 Ipsen Bioscience Inc. $1,121.95 06/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,855.92 06/12/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223281090
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,172.80 06/12/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050792
Principal investigator 1 GlaxoSmithKline, LLC. $2,438.37 06/10/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167835
Principal investigator 1 ABBVIE INC. $1,408.80 06/03/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202488249
Principal investigator 1 ABBVIE INC. $18,239.20 06/03/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202488251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,492.44 06/02/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280566
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659000
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659002
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659004
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659006
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659008
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220659010
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746844
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747004
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747032
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747034
Principal investigator 1 Ipsen Bioscience Inc. $90.00 06/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,085.24 05/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223280372
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,427.80 05/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050794
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746910
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746912
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746914
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746916
Principal investigator 1 Boehringer Ingelheim International GmbH $15.21 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746918
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746988
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746990
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746992
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746994
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 05/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746996
Principal investigator 1 Ipsen Bioscience Inc. $513.00 05/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546973
Principal investigator 1 Ipsen Bioscience Inc. $2,132.75 05/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546975
Principal investigator 1 GlaxoSmithKline, LLC. $27,073.75 05/26/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192164071
Principal investigator 1 Janssen Research & Development, LLC $4,512.00 05/23/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175417714
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747060
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747062
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747064
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747066
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747068
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747070
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747072
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 05/22/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747074
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,713.90 05/22/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050766
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 05/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183264
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183279
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183305
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 05/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183342
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 05/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183358
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183395
Principal investigator 1 GlaxoSmithKline, LLC. $1,136.03 05/09/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192112348
Principal investigator 1 ABBVIE INC. $1,045.00 05/07/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202483279
Principal investigator 1 Boehringer Ingelheim International GmbH $1.89 05/07/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746826
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 05/07/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746828
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/07/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746830
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/07/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746832
Principal investigator 1 ABBVIE INC. $1,778.60 05/06/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES INC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202481767
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658988
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658990
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658992
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658994
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658996
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658998
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746834
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746978
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746980
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746982
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746984
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220746986
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747028
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747030
Principal investigator 1 Ipsen Bioscience Inc. $90.00 05/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546971
Principal investigator 1 GlaxoSmithKline, LLC. $1,236.39 04/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192164098
Principal investigator 1 GlaxoSmithKline, LLC. $2,272.05 04/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192164648
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,178.84 04/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223278676
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 04/23/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747076
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 04/23/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747078
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 04/23/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747080
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 04/23/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747082
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 04/23/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747084
Principal investigator 1 Ipsen Bioscience Inc. $9,589.20 04/23/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546969
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 04/23/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183124
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 04/23/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183171
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/23/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183271
Principal investigator 1 Eli Lilly and Company $49,574.01 04/11/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187890120
Principal investigator 1 GlaxoSmithKline, LLC. $3,468.91 04/10/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192167819
Principal investigator 1 Ipsen Bioscience Inc. $2,132.75 04/08/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546963
Principal investigator 1 Ipsen Bioscience Inc. $4,230.97 04/08/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546965
Principal investigator 1 Ipsen Bioscience Inc. $1,551.60 04/08/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546967
Principal investigator 1 Bausch Health US, LLC $2,457.00 04/02/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843809
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658976
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658978
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658980
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658982
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658984
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658986
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746822
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747024
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747026
Principal investigator 1 Ipsen Bioscience Inc. $90.00 04/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546961
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,184.69 04/01/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223277248
Principal investigator 1 Janssen Research & Development, LLC $2,122.00 03/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175417707
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,746.22 03/26/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223277063
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 03/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746812
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746814
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 03/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746874
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 03/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746876
Principal investigator 1 Boehringer Ingelheim International GmbH $43.70 03/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746878
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 03/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746880
Principal investigator 1 GlaxoSmithKline, LLC. $5,223.71 03/21/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192164635
Principal investigator 1 Ipsen Bioscience Inc. $1,121.95 03/19/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546957
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,588.86 03/19/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223276773
Principal investigator 1 Ipsen Bioscience Inc. $6,114.20 03/11/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546953
Principal investigator 1 Ipsen Bioscience Inc. $2,312.10 03/11/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546955
Principal investigator 1 Janssen Research & Development, LLC $43,747.00 03/10/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175417731
Principal investigator 1 ABBVIE INC. $1,163.10 03/06/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202456284
Principal investigator 1 GlaxoSmithKline, LLC. $2,245.32 03/06/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167822
Principal investigator 1 Janssen Research & Development, LLC $2,122.00 03/06/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175417686
Principal investigator 1 PFIZER INC. $1,550.00 03/03/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228784750
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658962
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658964
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658966
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658968
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658970
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658972
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746824
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747020
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747022
Principal investigator 1 Ipsen Bioscience Inc. $90.00 03/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546959
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183083
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183090
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183099
Principal investigator 1 Janssen Research & Development, LLC $124.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183147
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183164
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183187
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183211
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183217
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183225
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183240
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/27/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175183295
Principal investigator 1 Boehringer Ingelheim International GmbH $48.29 02/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746794
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 02/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746800
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 02/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746802
Principal investigator 1 Boehringer Ingelheim International GmbH $4.81 02/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746804
Principal investigator 1 Boehringer Ingelheim International GmbH $4.81 02/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746806
Principal investigator 1 Boehringer Ingelheim International GmbH $4.81 02/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746808
Principal investigator 1 Boehringer Ingelheim International GmbH $4.81 02/25/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746810
Principal investigator 1 GlaxoSmithKline, LLC. $2,245.32 02/24/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167815
Principal investigator 1 GlaxoSmithKline, LLC. $5,525.35 02/24/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192167830
Principal investigator 1 Janssen Research & Development, LLC $23,755.00 02/24/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175417680
Principal investigator 1 Ipsen Bioscience Inc. $513.00 02/18/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546949
Principal investigator 1 Janssen Research & Development, LLC $29,425.00 02/17/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175417672
Principal investigator 1 Bausch Health US, LLC $1,910.00 02/07/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843791
Principal investigator 1 Bausch Health US, LLC $516.00 02/07/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843794
Principal investigator 1 Celgene Corporation $11,798.00 02/05/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222306751
Principal investigator 1 PFIZER INC. $4,054.00 02/03/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228775237
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658950
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658952
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658954
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658956
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658958
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658960
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746842
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747016
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747018
Principal investigator 1 Ipsen Bioscience Inc. $90.00 02/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546951
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192112352
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192112359
Principal investigator 1 GlaxoSmithKline, LLC. $10,000.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192164075
Principal investigator 1 GlaxoSmithKline, LLC. $800.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192164083
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192164644
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192164657
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192164665
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192167811
Principal investigator 1 GlaxoSmithKline, LLC. $161.20 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192167826
Principal investigator 1 GlaxoSmithKline, LLC. $80.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192169228
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192169232
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192169240
Principal investigator 1 Janssen Research & Development, LLC $4,028.00 01/31/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES PC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175417659
Principal investigator 1 Janssen Research & Development, LLC $2,226.00 01/30/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates Colorado Spgs
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175183387
Principal investigator 1 Ipsen Bioscience Inc. $2,132.75 01/29/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546947
Principal investigator 1 GlaxoSmithKline, LLC. $4,474.39 01/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192164091
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 01/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192169212
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 01/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192169220
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 01/28/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
A TWO-PART, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, MULTICENTER, No dispute reported 06/30/2026 1192169236
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746796
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746798
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746816
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746818
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746820
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746850
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746852
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746854
Principal investigator 1 Boehringer Ingelheim International GmbH $549.63 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746856
Principal investigator 1 Boehringer Ingelheim International GmbH $262.20 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746858
Principal investigator 1 Boehringer Ingelheim International GmbH $4.05 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746860
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746862
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746864
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746866
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746868
Principal investigator 1 Boehringer Ingelheim International GmbH $21.96 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746870
Principal investigator 1 Boehringer Ingelheim International GmbH $52.50 01/27/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220746872
Principal investigator 1 Ipsen Bioscience Inc. $6,114.20 01/17/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546945
Principal investigator 1 Bausch Health US, LLC $1,813.00 01/08/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843799
Principal investigator 1 Bausch Health US, LLC $1,615.00 01/08/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843804
Principal investigator 1 GlaxoSmithKline, LLC. $3,595.18 01/08/2025 Non-covered Recipient Entity
PEAK GASTROENTEROLOGY ASSOCIATES
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192164652
Principal investigator 1 Ipsen Bioscience Inc. $2,469.60 01/07/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176546941
Principal investigator 1 Ipsen Bioscience Inc. $1,950.68 01/07/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546943
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658940
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658942
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658944
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658946
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658948
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates-Briargate
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658974
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220746792
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747012
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Future Innovative Treatments LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747014
Principal investigator 1 Ipsen Bioscience Inc. $90.00 01/01/2025 Non-covered Recipient Entity
Peak Gastroenterology Associates, Pc
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546939